Department of Radiation Oncology, Xijing Hospital.
State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, People's Republic of China.
Int J Surg. 2023 Aug 1;109(8):2451-2466. doi: 10.1097/JS9.0000000000000441.
Due to tumoral heterogeneity and the lack of robust biomarkers, the prediction of chemoradiotherapy response and prognosis in patients with esophageal cancer (EC) is challenging. The goal of this study was to assess the study quality and clinical value of machine learning and radiomic-based quantitative imaging studies for predicting the outcomes of EC patients after chemoradiotherapy.
PubMed, Embase, and Cochrane were searched for eligible articles. The methodological quality and risk of bias were evaluated using the Radiomics Quality Score (RQS), Image Biomarkers Standardization Initiative (IBSI) Guideline, and Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) statement, as well as the modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. A meta-analysis of the evidence focusing on predicting chemoradiotherapy response and outcome in EC patients was implemented.
Forty-six studies were eligible for qualitative synthesis. The mean RQS score was 9.07, with an adherence rate of 42.52%. The adherence rates of the TRIPOD and IBSI were 61.70 and 43.17%, respectively. Ultimately, 24 studies were included in the meta-analysis, of which 16 studies had a pooled sensitivity, specificity, and area under the curve (AUC) of 0.83 (0.76-0.89), 0.83 (0.79-0.86), and 0.84 (0.81-0.87) in neoadjuvant chemoradiotherapy datasets, as well as 0.84 (0.75-0.93), 0.89 (0.83-0.93), and 0.93 (0.90-0.95) in definitive chemoradiotherapy datasets, respectively. Moreover, radiomics could distinguish patients from the low-risk and high-risk groups with different disease-free survival (DFS) (pooled hazard ratio: 3.43, 95% CI 2.39-4.92) and overall survival (pooled hazard ratio: 2.49, 95% CI 1.91-3.25). The results of subgroup and regression analyses showed that some of the heterogeneity was explained by the combination with clinical factors, sample size, and usage of the deep learning (DL) signature.
Noninvasive radiomics offers promising potential for optimizing treatment decision-making in EC patients. However, it is necessary to make scientific advancements in EC radiomics regarding reproducibility, clinical usefulness analysis, and open science categories. Improved model reporting of study objectives, blind assessment, and image processing steps are required to help promote real clinical applications of radiomics in EC research.
由于肿瘤异质性和缺乏稳健的生物标志物,预测食管癌(EC)患者的放化疗反应和预后具有挑战性。本研究旨在评估基于机器学习和放射组学的定量成像研究在预测 EC 患者放化疗后结局方面的研究质量和临床价值。
在 PubMed、Embase 和 Cochrane 中检索符合条件的文献。使用放射组学质量评分(RQS)、图像生物标志物标准化倡议(IBSI)指南和用于个体预后或诊断的多变量预测模型的透明报告(TRIPOD)声明,以及改良的诊断准确性研究质量评估工具(QUADAS-2)工具来评估方法学质量和偏倚风险。对专注于预测 EC 患者放化疗反应和结局的证据进行了荟萃分析。
46 项研究有资格进行定性综合分析。平均 RQS 评分为 9.07,一致性率为 42.52%。TRIPOD 和 IBSI 的一致性率分别为 61.70%和 43.17%。最终,24 项研究纳入荟萃分析,其中 16 项研究在新辅助放化疗数据集的汇总敏感性、特异性和曲线下面积(AUC)分别为 0.83(0.76-0.89)、0.83(0.79-0.86)和 0.84(0.81-0.87),在根治性放化疗数据集的汇总敏感性、特异性和 AUC 分别为 0.84(0.75-0.93)、0.89(0.83-0.93)和 0.93(0.90-0.95)。此外,放射组学可以区分出无病生存率(DFS)(汇总风险比:3.43,95%CI 2.39-4.92)和总生存率(汇总风险比:2.49,95%CI 1.91-3.25)不同的低风险和高风险组的患者。亚组和回归分析的结果表明,某些异质性可以通过与临床因素、样本量和深度学习(DL)特征的结合来解释。
非侵入性放射组学为优化 EC 患者的治疗决策提供了有前景的潜力。然而,需要在 EC 放射组学领域在可重复性、临床实用性分析和开放科学类别方面取得科学进展。需要改进研究目标、盲法评估和图像处理步骤的模型报告,以帮助促进放射组学在 EC 研究中的实际临床应用。